Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

Sean A Misek, Patrick A Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I Doseff, Bin Chen, Kathleen A Gallo and Richard R. Neubig
Molecular Pharmacology November 3, 2021, MOLPHARM-AR-2021-000331; DOI: https://doi.org/10.1124/molpharm.121.000331
Sean A Misek
1Broad Institute, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick A Newbury
2Michigan State University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evgenii Chekalin
2Michigan State University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shreya Paithankar
3Michigan State Universisty, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea I Doseff
2Michigan State University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Chen
2Michigan State University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen A Gallo
2Michigan State University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rneubig@msu.edu
Richard R. Neubig
4Pharmacology and Toxicology, Michigan State, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rneubig@msu.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

MOLPHARM-AR-2021-000331
DOI 
https://doi.org/10.1124/molpharm.121.000331
PubMed 
34732527

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Published online November 3, 2021.

Article Versions

  • You are currently viewing an Earlier version of this article (November 3, 2021 - 01:46).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Sean A Misek1,
  2. Patrick A Newbury2,
  3. Evgenii Chekalin2,
  4. Shreya Paithankar3,
  5. Andrea I Doseff2,
  6. Bin Chen2,
  7. Kathleen A Gallo2,*, and
  8. Richard R. Neubig4,*
  1. 1Broad Institute, United States
  2. 2Michigan State University, United States
  3. 3Michigan State Universisty, United States
  4. 4Pharmacology and Toxicology, Michigan State, United States
  1. ↵* Corresponding Author:
    Richard R. Neubig, Pharmacology and Toxicology, Michigan State, 1355 Bogue St, B440 Life Sciences Building, East Lansing, Michigan, 48824, United States. E-mail: rneubig{at}msu.edu
  2. * Corresponding Author; email: gallok{at}msu.edu

Statistics from Altmetric.com

Article usage

Article usage: November 2021 to March 2023

AbstractFullPdf
Nov 20213840153
Dec 20214772199
Jan 20223993258
Feb 20221753424
Mar 20221162128
Apr 2022205912
May 20221201934
Jun 2022601120
Jul 202280814
Aug 202294126
Sep 20221041411
Oct 2022105107
Nov 2022522617
Dec 2022323115
Jan 202353925
Feb 2023103527
Mar 2023123113

Next
Back to top

In this issue

Molecular Pharmacology: 103 (4)
Molecular Pharmacology
Vol. 103, Issue 4
1 Apr 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Ibrutinib re-sensitizes BRAFi-resistant melanoma

Sean A Misek, Patrick A Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I Doseff, Bin Chen, Kathleen A Gallo and Richard R. Neubig
Molecular Pharmacology November 3, 2021, MOLPHARM-AR-2021-000331; DOI: https://doi.org/10.1124/molpharm.121.000331

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Ibrutinib re-sensitizes BRAFi-resistant melanoma

Sean A Misek, Patrick A Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I Doseff, Bin Chen, Kathleen A Gallo and Richard R. Neubig
Molecular Pharmacology November 3, 2021, MOLPHARM-AR-2021-000331; DOI: https://doi.org/10.1124/molpharm.121.000331
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics